PLSE — Start of Clinical Trial for CellFX® nsPFA Cardiac Surgery Clamp System
Jul 1, 2025, 5:00:00 AM UTC
Summary
Pulse Biosciences, Inc. announced that enrollment for its clinical trial of the CellFX® Nanosecond Pulsed Field Ablation (nsPFA) system, aimed at treating Atrial Fibrillation, will commence in July 2025. The trial, identified as NCT06959121, will be a multicenter, two-arm, randomized, controlled study involving 165 adult subjects. Participants will either receive an ablation procedure alongside standard cardiac surgery or undergo standard surgery without ablation. The trial's primary endpoint focuses on assessing major adverse events within 30 days post-surgery, with anticipated completion by January 2027.
Company
PULSE BIOSCIENCES INC (PLSE)NASDAQ — Healthcare: Manufacturing, Medical Instruments & Supplies: Surgical & Medical Instruments & Apparatus
www.pulsebiosciences.comSimilar Events
Expected Completion of Clinical Trial for CellFX® nsPFA™ Cardiac Surgery System
Pulse Biosciences, Inc. is expected to complete a clinical trial studying its CellFX® nsPFA™ Cardiac Surgery System for the treatment of atrial fibrillation on October 31, 2025. This prospective, multicenter feasibility study aims to evaluate the safety and effectiveness of the device in combination with cardiac surgery. The trial is currently recruiting, targeting an enrollment of 30 adult subjects who are indicated for concomitant cardiac surgical procedures. Participants will undergo ablation procedures, with follow-up electrophysiology studies scheduled between 60-120 days post-surgery to assess the outcomes of the treatment.
Clinical Trial CompletionExpected completion of clinical trial for CellFX® Nano-Pulsed Field Ablation 360 Catheter.
Pulse Biosciences, Inc. anticipates the completion of its clinical trial evaluating the CellFX® Nano-Pulsed Field Ablation 360 Catheter for treating paroxysmal atrial fibrillation on April 25, 2026. This trial is a first-in-human feasibility study assessing the device's safety and performance, with an enrollment of 60 participants. Subjects will be monitored for up to 12 months post-ablation, focusing on the evaluation of pulmonary vein isolation. This study is currently in the recruiting phase and commenced on July 25, 2024.
clinical trial completionStart of HELIX Clinical Trial for Helix Surgical System
A clinical trial for the Helix Surgical System, sponsored by Sight Sciences, Inc., is set to start on May 30, 2025. This trial will assess the safety of the system in cataract surgery and evaluate its effectiveness in lowering intraocular pressure in patients with mild to moderate primary open-angle glaucoma (POAG). The trial is currently recruiting 25 participants and is expected to be completed by September 30, 2026. This trial could provide crucial information that may influence the financial outlook for SGHT, as positive outcomes could enhance the product's market adoption and financial performance.
clinical trial startStart of Clinical Trials
Generation Bio Co. plans to initiate clinical trials for its novel cell-targeted lipid nanoparticle (ctLNP) delivery technology to develop siRNA therapeutics aimed at T cell-driven autoimmune diseases by June 30, 2027. This initiative follows a strategic pivot announced on January 6, 2025, as part of a broader corporate restructuring, including a workforce reduction of approximately 20% to align resources with the new focus. The company anticipates submitting its first investigational new drug application in late 2026, with substantial severance and restructuring costs estimated between $1 million and $2 million expected by the second quarter of 2025. Generation Bio's financial position is supported by a cash runway that is projected to extend into the second half of 2027.
Clinical Trials Start